INOVIQ (ASX:IIQ) has announced encouraging blood test identification results for ovarian cancer.
On completion of its “analytical validation study”, the biotechnology company said the tests had “correctly” identified 85% of all samples tested.
This comprised 76% of cancer-positive samples compared to 94% cancer free samples.
Inoviq did not refer to previous test results for comparative purposes, but is presenting its blood test solution for cancer tests as a simple, accurate and affordable combination immonouassay.
It was developed using a CA125 monoclonal antibody used by leading diagnostic companies, combined with Inoviq’s SubB2M detection reagent.
Inoviq said: “The addition of SubB2M ensures that the test only detects CA125 that is produced by cancer cells, resulting in improved specificity for cancer and potentially a reduced number of false positive test results.”
The Melbourne headquartered company is also striving to develop tests to detect breast cancer and includes a team of 19 based researchers in the United States with 11 of those holding 8 PhDs.
Research, development and clinical testing takes place at the company’s cGMP approved production site.
Inoviq was down 3% in early trade at 62 cents.